|
1.
|
|
9 p, 267.2 KB |
A Topical Treatment Optimization Programme (TTOP) improves clinical outcome for calcipotriol/betamethasone gel in psoriasis : results of a 64-week multinational randomized phase IV study in 1790 patients (PSO-TOP)
/
Reich, Kristian (SCIderm GmbH) ;
Zschocke, I. (SCIderm GmbH) ;
Bachelez, Hervé (AP-HP Hôpital Saint-Louis) ;
de Jong, E.M.G.J. (Radboud University Medical Centre and Radboud University) ;
Gisondi, Paolo (University of Verona) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Warren, R. B. (Manchester Academic Health Science Centre) ;
Ortland, C. (Das Forschungsdock Service for Clinical Development) ;
Mrowietz, Ulrich (University Medical Center Schleswig-Holstein) ;
Universitat Autònoma de Barcelona
Around two-thirds of patients with psoriasis do not adhere to topical treatment. The Topical Treatment Optimization Programme (TTOP), a five-element tool, includes guidance for the conversation between dermatologists/nurses and patients, patient information material, telephone/e-mail helpdesks and treatment reminders. [...]
2017 -  10.1111/bjd.15466
British journal of dermatology, Vol. 177 Núm. 1 (july 2017) , p. 197-205
|
|
|
2.
|
|
6 p, 377.9 KB |
Clinical and genetic differences between pustular psoriasis subtypes
/
Twelves, Sophie (King's College London) ;
Mostafa, Alshimaa (Beni Suef University) ;
Dand, Nick (King's College London) ;
Burri, Elias (University Hospital Zurich (Suïssa)) ;
Farkas, K. (University of Szeged) ;
Wilson, Rosemary (King's College London) ;
Cooper, Hywel L. (Portsmouth Hospitals Trust) ;
Irvine, Alan D. (Trinity College Dublin) ;
Oon, Hazel H. (National Skin Centre) ;
Kingo, Külli (Tartu University Hospital (Tartu, Estònia)) ;
Köks, Sulev (University of Tartu) ;
Mrowietz, Ulrich (University Medical Center Schleswig-Holstein) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Reynolds, Nick (Newcastle Hospitals NHS Foundation Trust) ;
Tan, Euegene Sern-Ting (National Skin Centre) ;
Tanew, Adrian (Medical University of Vienna) ;
Torz, Kaspar (Campus Kiel) ;
Trattner, Hannes (Medical University of Vienna) ;
Valentine, Mark (University of Washington School of Medicine) ;
Wahie, Shyamal (University Hospital of North Durham and Darlington Memorial Hospital) ;
Warren, Richard B. (University of Manchester and the Academic Health Science Centre) ;
Wright, Andrew (St University of Bradford) ;
Bata-Csörgő, Zsuzsa (University of Szeged) ;
Szell, Marta (University of Szeged) ;
Griffiths, Christopher E.M. (University of Manchester and the Academic Health Science Centre) ;
Burden, A.David (University of Glasgow) ;
Choon, Siew-Eng (Monash University Malaysia) ;
Smith, Catherine H. (King's College London) ;
Barker, Jonathan N. (King's College London) ;
Navarini, Alexander A. (University Hospital Zurich (Suïssa)) ;
Capon, Francesca (King's College London) ;
Universitat Autònoma de Barcelona
The term pustular psoriasis indicates a group of severe skin disorders characterized by eruptions of neutrophil-filled pustules. The disease, which often manifests with concurrent psoriasis vulgaris, can have an acute systemic (generalized pustular psoriasis [GPP]) or chronic localized (palmoplantar pustulosis [PPP] and acrodermatitis continua of Hallopeau [ACH]) presentation. [...]
2019 - 10.1016/j.jaci.2018.06.038
The Journal of Allergy and Clinical Immunology, Vol. 143 Núm. 3 (march 2019) , p. 1021-1026
|
|
|
3.
|
|
9 p, 1013.2 KB |
Long-term efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis : a post hoc pooled analysis of AMAGINE-2 and -3
/
Reich, Kristian (University Medical Center Hamburg-Eppendorf) ;
Iversen, L. (Aarhus University Hospital (Aarhus, Dinamarca)) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Lambert, Jo (Ghent University) ;
Mrowietz, Ulrich (University Medical Center Schleswig-Holstein) ;
Kaplan Saday, K. (LEO Pharma A/S) ;
Warren, R. B. (University of Manchester) ;
Universitat Autònoma de Barcelona
Brodalumab is a monoclonal antibody that blocks multiple interleukin (IL)-17 family cytokines by binding to the shared A subunit of the IL-17 receptor. In Phase 3 trials, brodalumab provided high levels of skin clearance through 52 weeks in patients with moderate-to-severe psoriasis and was generally well tolerated. [...]
2022 - 10.1111/jdv.18068
Journal of the European Academy of Dermatology and Venereology, Vol. 36 Núm. 8 (august 2022) , p. 1275-1283
|
|
|
4.
|
|
3 p, 1.3 MB |
Vaccine hesitancy and access to psoriasis care during the -19 pandemic : findings from a global patient-reported cross-sectional survey
/
Bechman, Katie (King's College London) ;
Cook, Emma S. (King's College London) ;
Dand, Nick (Health Data Research UK) ;
Yiu, Zenas Z.N. (The University of Manchester) ;
Tsakok, Teresa (King's College London) ;
Meynell, Freya (King's College London) ;
Coker, Bolaji (King's College London) ;
Vincent, Alexandra (King's College London) ;
Bachelez, Hervé (Université de Paris) ;
Barbosa, Ines (King's College London) ;
Brown, Matthew A. (King's College London) ;
Capon, Francesca (King's College London) ;
Contreras, Claudia R. (Universidad Nacional de Asuncion) ;
De La Cruz, Claudia (Clinica Dermacross) ;
Di Meglio, Paola (King's College London) ;
Gisondi, Paolo (University of Verona) ;
Jullien, Denis (Groupe de recherche sur le psoriasis (GrPso) de la Société Française de dermatologie) ;
Kelly, Jade (NIHR Manchester Biomedical Research Centre) ;
Lambert, Jo (Ghent University) ;
Lancelot, Camille (International Federation of Psoriasis Associations) ;
Langan, Sinead M. (London School of Hygiene and Tropical Medicine) ;
Mason, Kayleigh J. (Keele University) ;
McAteer, Helen (The Psoriasis Association) ;
Moorhead, Lucy (King's College London) ;
Naldi, Luigi (Centro Studi GISED) ;
Norton, Sam (King's College London) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Spuls, Phyllis I. (Amsterdam UMC. University Medical Center) ;
Torres, Tiago (Centro Hospitalar do Porto) ;
Urmston, Dominic (The Psoriasis Association) ;
Vesty, Amber (The Psoriasis Association) ;
Warren, Richard B. (NIHR Manchester Biomedical Research Centre) ;
Waweru, Hoseah (International Federation of Psoriasis Associations) ;
Weinman, John (King's College London) ;
Griffiths, Christopher E.M. (NIHR Manchester Biomedical Research Centre) ;
Barker, Jonathan (King's College London) ;
Smith, Catherine H. (King's College London) ;
Galloway, James B. (King's College London) ;
Mahil, Satveer K. (King's College London) ;
Universitat Autònoma de Barcelona
2022 - 10.1111/bjd.21042
British journal of dermatology, Vol. 187 (may 2022) , p. 254-256
|
|
|
5.
|
|
24 p, 525.4 KB |
Elevating the Standard of Care for Patients with Psoriasis : 'Calls to Action' from Epicensus, a Multistakeholder Pan-European Initiative
/
Koren, Jan (EUROPSO, Polzela, Slovenia) ;
Lambert, Jo (Ghent University) ;
Thomsen, Simon F. (University of Copenhagen) ;
McAteer, Helen (Psoriasis Association) ;
Fabbrocini, Gabriella (University of Naples Federico II) ;
Corazza, Valeria (Italian Psoriatic Association Friends of the Corazza Foundation) ;
Jullien, Denis (Lyon-1 University) ;
Augustin, Matthias (University Medical Center Hamburg-Eppendorf) ;
Warren, Richard B. (University of Manchester) ;
de Rie, Menno A. (University of Amsterdam) ;
Lazaridou, Elizabeth (Aristotle University School of Medicine) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Guillevin, Loïc (Université Paris Descartes) ;
Grosser, Marius (German Psoriasis Association) ;
Boehncke, Wolf-Henning (University of Geneva) ;
Universitat Autònoma de Barcelona
Despite advances in treatment options and the management of patients with psoriasis, considerable unmet needs remain. Our objective was to identify ways to elevate the standard of care for patients with psoriasis by combining the perspectives of three important stakeholders: patients, clinicians and payors, and define 'Calls to Action' designed to achieve the identified changes. [...]
2022 - 10.1007/s13555-022-00846-3
Dermatology and Therapy, december 2022, p. 1-24
|
|
|
6.
|
|
11 p, 652.6 KB |
Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type : a cross-sectional patient survey*
/
Mahil, Satveer K. ;
Yates, Mark (King's College London) ;
Langan, Sinead M. (London School of Hygiene and Tropical Medicine) ;
Yiu, Zenas Z.N. ;
Tsakok, Teresa ;
Dand, Nick ;
Mason, Kayleigh J. ;
McAteer, Helen ;
Meynell, Freya ;
Coker, Bolaji ;
Vincent, A. (Guy's and St Thomas' NHS Foundation Trust) ;
Urmston, Dominic ;
Vesty, Amber ;
Kelly, J. (The University of Manchester) ;
Lancelot, Camille (France Veterinary International) ;
Moorhead, Lucy (Guy's and St Thomas' NHS Foundation Trust) ;
Bachelez, Hervé (Université Paris Cité) ;
Bruce, I.N. (The University of Manchester) ;
Capon, Francesca (King's College London) ;
Contreras, Claudia Romina (Universidad Nacional de Asunción) ;
Cope, Andrew P. (Kingston College United Kingdom) ;
De La Cruz, C. (University of Santiago, Chile) ;
Di Meglio, Paola (Newcastle University) ;
Gisondi, Paolo (University of Verona) ;
Hyrich, Kimme (The University of Manchester) ;
Jullien, Denis (Hospices Civils de Lyon (Centre Hospitalier Universitaire de Lyon)) ;
Lambert, Julien ;
Marzo-Ortega, H. (Leeds Teaching Hospitals NHS Trust) ;
McInnes, Iain B. (University of Glasgow) ;
Naldi, L. (San Bortolo Hospital) ;
Norton, Sam (King's College London) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Sengupta, Raj (Royal National Hospital For Rheumatic Diseases NHS Foundation Trust) ;
Spuls, Phyllis (University of Amsterdam) ;
Torres, Tiago (Centro Hospitalar e Universitário do Porto) ;
Warren, Richard B. (The University of Manchester) ;
Waweru, Hoseah (Upper Hill Medical Centre) ;
Weinman, John (King's College London) ;
Griffiths, Chris E.M. (The University of Manchester) ;
Barker, Jonathan (The Kings College) ;
Brown, Matthew A. (Guy's and St Thomas' NHS Foundation Trust) ;
Galloway, James B. ;
Smith, Catherine (King's College London)
Background: Registry data suggest that people with immune-mediated inflammatory diseases (IMIDs) receiving targeted systemic therapies have fewer adverse coronavirus disease 2019 (COVID-19) outcomes compared with patients receiving no systemic treatments. [...]
2021 - 10.1111/bjd.19755
British journal of dermatology, Vol. 185 Núm. 1 (july 2021) , p. 80-90
|
|
|
7.
|
|
|
8.
|
|
|
9.
|
|
|
10.
|
|
13 p, 3.0 MB |
Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis : pooled analyses of two randomized phase clinical trials (re 1 and re 2) through 148 weeks
/
Reich, Kristian (Dermatologikum Berlin) ;
Warren, R. B. (The University of Manchester. Manchester NIHR Biomedical Research Centre. Salford Royal NHS Foundation Trust) ;
Iversen, Lars (Aarhus University Hospital (Aarhus, Dinamarca)) ;
Puig Sanz, Lluís. (Institut d'Investigació Biomèdica Sant Pau) ;
Pau-Charles, I. (Almirall R&D) ;
Igarashi, A. (NTT Medical Center Tokyo) ;
Ohtsuki, M. (Jichi Medical University) ;
Falqués, M. (Almirall R&D) ;
Harmut, M. (Almirall R&D) ;
Rozzo, S. (Sun Pharmaceuticals) ;
Lebwohl, M. G. (Icahn School of Medicine at Mount Sinai) ;
Cantrell, W. (University of Alabama at Birmingham) ;
Blauvelt, Andrew (Oregon Medical Research Center) ;
Thaçi, Diamant (University of Lübeck) ;
Universitat Autònoma de Barcelona
Tildrakizumab is a specific anti-interleukin-23p19 monoclonal antibody approved for the treatment of plaque psoriasis. To evaluate the long-term efficacy and safety of tildrakizumab treatment for patients with moderate-to-severe psoriasis for up to 148 weeks. [...]
2019 - 10.1111/bjd.18232
British journal of dermatology, Vol. 182 (july 2019) , p. 605-617
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
